High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Dong Ho LeeHong Il HaJin-Young JangJung Woo LeeJin-Young ChoiSeungmin BangChang Hee LeeWan Bae KimSeung Soo LeeSong Cheol KimBo-Kyeong KangJeong Min LeePublished in: European radiology (2023)
• The margin-negative (R0) resection rates were 88.7% (47/53), 52.4% (11/21), and 0.0% (0/4) for resectable, borderline resectable, and unresectable pancreatic ductal adenocarcinoma (PDAC), respectively, on 80-kVp thin-section pancreatic CT in the 78 patients who underwent upfront surgery. • Among the 60 patients who underwent neoadjuvant therapy, the R0 rates were 90.9% (20/22), 76.7% (23/30), and 25.0% (2/8) for resectable, borderline resectable, and unresectable PDAC, respectively. • Tumor response, along with the resectability status on pancreatic CT, was significantly associated with the R0 resection rate after neoadjuvant therapy.
Keyphrases
- locally advanced
- computed tomography
- end stage renal disease
- newly diagnosed
- liver metastases
- chronic kidney disease
- rectal cancer
- high resolution
- image quality
- ejection fraction
- peritoneal dialysis
- dual energy
- magnetic resonance imaging
- positron emission tomography
- stem cells
- minimally invasive
- radiation therapy
- bone marrow
- clinical trial
- acute coronary syndrome
- mesenchymal stem cells
- percutaneous coronary intervention
- replacement therapy
- smoking cessation
- surgical site infection